Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oxyprim Gout Therapy To Be Limited To Allopurinol Failures, Cardiome Says

Executive Summary

Cardiome's risk management plan for the chronic gout therapy Oxyprim would require proof of patient failure on standard therapy before administration, Exec VP-Clinical Development Alan Moore, PhD, said June 2

You may also be interested in...



Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting

Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting

Cardiome Oxyprim is “approvable”

Cardiome is assessing whether to continue development of Oxyprim (oxypurinol) for allopurinol-intolerant hyperuricemia following an FDA "approvable" letter. FDA Arthritis Advisory Committee expressed dissatisfaction with the protocol for the pivotal Phase II trial during a June 2 meeting (1"The Pink Sheet" June 7, 2004, p. 40)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel